From the Food and Drug Administration.
Nightingale
S L
SL
D003550:Cystic Fibrosis / Q000188:drug therapy*; D003850:Deoxyribonuclease I; D003851:Deoxyribonucleases / Q000627:therapeutic use*; D017277:Drug Approval; D004359:Drug Therapy, Combination; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D009288:Naproxen / Q000008:administration & dosage*; D004366:Nonprescription Drugs; D009965:Orphan Drug Production; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D016597:Trimetrexate / Q000008:administration & dosage / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D004366:Nonprescription Drugs; D011994:Recombinant Proteins; D009288:Naproxen; D003851:Deoxyribonucleases; C085693:DNASE1 protein, human; D003850:Deoxyribonuclease I; D002955:Leucovorin; D016597:Trimetrexate